Biotech News

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Harmony Biosciences (HRMY)Harmony BiosciencesConference / presentation

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia.

Related news

HRMYHarmony Biosciences2026-11-19 13:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-09-22 12:30 EST

Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community

NBIXNeurocrine Biosciences2026-11-10 21:01 EST

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

SUPNSupernus2026-11-10 13:30 EST

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

CGTXCognition Therapeutics2026-11-09 12:30 EST

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

Stock data

Close
32.98 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States